GlassScriptPhysician profile
Jorge A Ortiz
NPI 1154388809
$7,291.68
in general payments reported to CMS, 2019-2025
24 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2021: $92.75 · 2022: $4,369 · 2023: $577 · 2024: $304 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321 · Travel and Lodging: $245 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,320.97 |
| Travel and Lodging | $244.60 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $4,205.40 | 2021-2023 | |
| Kci USA, INC. | $558.63 | 2019 | |
| Stryker Corporation | $476.11 | 2021-2025 | 1788, Spy-Phi System |
| Veloxis Pharmaceuticals, INC. | $298.53 | 2019-2022 | |
| Medical Device Business Services, INC. | $202.53 | 2023 | Stratafix |
| Eurofins Viracor, LLC | $198.99 | 2024 | |
| W. L. Gore & Associates, INC. | $173.70 | 2025 | Gore Synecor Biomaterial |
| Davol INC. | $133.13 | 2024-2025 | Phasix Mesh |
| Astrazeneca Pharmaceuticals LP | $124.95 | 2023 | Lokelma |
| Heron Therapeutics, INC. | $124.91 | 2025 | Zynrelef |
| Karl Storz Endoscopy-America | $122.27 | 2019-2025 | Spies |
| Boston Scientific Corporation | $121.01 | 2025 | Spyglass Discover |
| Vifor Pharma, INC. | $109.61 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $87.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.17 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $72.09 | 2022 | |
| Baxter Healthcare | $35.04 | 2019 | |
| Ethicon US, LLC | $33.84 | 2025 | Dermabond |
| Medtronic, INC. | $32.92 | 2025 | Signia |
| Janssen Scientific Affairs, LLC | $30.75 | 2019 | |
| Integra Lifesciences Corporation | $19.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.98 | 2019 | |
| Glaxosmithkline, LLC. | $13.49 | 2025 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.